Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: A single institution's experience

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 420-423

  Ivy, Joseph J ^a   Geller, Melissa ^a   Pierson, Serena M ^a   Jonson, Amy L ^a   Argenta, Peter A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Catheter; Chemotherapy; Complication; Intraperitoneal; Ovarian cancer; Port

Indexed keywords

CISPLATIN; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CATHETER COMPLICATION; CATHETER INFECTION; COMORBIDITY; CYTOREDUCTIVE SURGERY; DRUG DELIVERY SYSTEM; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY REACTION; INTRAPERITONEAL CHEMOTHERAPY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OUTCOME ASSESSMENT; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; SURGICAL TECHNIQUE; UTERINE TUBE CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETERS, INDWELLING; CISPLATIN; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; TREATMENT OUTCOME;

EID: 67651146339     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.05.036     Document Type: Article

References (23)

1. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 4 (1994) 974-979
2. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al., Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 17 (2003) 3194-3200
3. Mohamed F.M.P., Stuart O.A., and Sugarbaker P. Pharmokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother. Pharmacol. 52 5 (2003) 6
4. Dedrick R.L., Myers C.E., Bungay P.M., and DeVita Jr. V.T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62 1 (1978) 1-11
5. Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat. Rev. 13 4 (1986) 219-242
6. Markman M. Cytotoxic intracavitary chemotherapy. Am. J. Med. Sci. 291 3 (1986) 175-179
7. Howell S.B. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int. J. Gynecol. Cancer 18 Suppl 1 (2008) 20-25
8. Howell S.B., Pfeifle C.L., Wung W.E., Olshen R.A., Lucas W.E., Yon J.L., et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97 6 (1982) 845-851
9. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al., Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 1 (2006) 34-43
10. Walker J.L., Armstrong D.K., Huang H.Q., Fowler J., Webster K., Burger R.A., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol. Oncol. 100 1 (2006) 27-32
11. Landrum L.M., Gold M.A., Moore K.N., Myers T.K., McMeekin D.S., and Walker J.L. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol. Oncol. 108 2 (2008) 342-347
12. Black D., Levine D.A., Nicoll L., Chou J.F., Iasonos A., Brown C.L., et al. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol. Oncol. 109 1 (2008) 39-42
13. Intraperitoneal chemotherapy for ovarian cancer NCI announcement, available January 2006 at ctep.Cancergov/highlights/docs/clin_annc_010506.pdf.
14. Kirmani S., Braly P.S., McClay E.F., Saltzstein S.L., Plaxe S.C., Kim S., et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol. Oncol. 54 3 (1994) 338-344
15. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 26 (1996) 1950-1955
16. Polyzos A., Tsavaris N., Kosmas C., Giannikos L., Katsikas M., Kalahanis N., et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 56 4 (1999) 291-296
17. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 4 (2001) 1001-1007
18. Yen M.S., Juang C.M., Lai C.R., Chao G.C., Ng H.T., and Yuan C.C. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int. J. Gynaecol. Obstet. 72 1 (2001) 55-60
19. Gadducci A., Carnino F., Chiara S., Brunetti I., Tanganelli L., Romanini A., et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol. Oncol. 76 2 (2000) 157-162
20. Makhija S., Leitao M., Sabbatini P., Bellin N., Almadrones L., Leon L., et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol. Oncol. 81 1 (2001) 77-81
21. Davidson S.A., Rubin S.C., Markman M., Jones W.B., Hakes T.B., Reichman B., et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol. Oncol. 41 2 (1991) 101-106
22. Braly P., Doroshow J., and Hoff S. Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis. Gynecol. Oncol. 25 3 (1986) 319-333
23. Sakuragi N., Nakajima A., Nomura E., Noro N., Yamada H., Yamamoto R., et al. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma. Gynecol. Oncol. 79 3 (2000) 420-423